New program seeks to expand access to patients suffering from multiple sclerosis (MS)
NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (“PTAP”), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (“PoNS”) Therapy at a significantly reduced price. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from multiple sclerosis (“MS”) and is available by prescription only.
“In April, we announced that the first patients in the United States had purchased the PoNS device on a cash pay basis and begun treatment. We are also offering an opportunity for MS patients to be treated with PoNS Therapy™ through our previously announced Therapeutic Experience Program (“TEP”), gathering important clinical evidence in a real-world environment while we pursue reimbursement from third-party payers and CMS. Our goal is to bring treatment to as many qualifying patients as possible and we are proud to introduce our Patient Therapy Access Program for potential first-time users,” stated Dane Andreeff, President and Chief Executive Officer of Helius.
“With the proper prescription and a letter of medical necessity, people struggling with MS in the U.S. will be able to access PoNS Therapy at a greatly reduced price. We believe this program will accelerate the adoption of PoNS Therapy and help to establish PoNS as the standard of care for MS patients with gait deficit. PTAP participants will also be invited to join Helius’s upcoming registry program, which is designed to collect important health economic information to establish the value of PoNS on key therapeutic outcomes and will complement the data gleaned through TEP,” concluded Mr. Andreeff.
The PTAP is currently available and expected to run through December 31, 2022.
Recent HSDT News
- Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) • GlobeNewswire Inc. • 08/16/2024 09:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:15:30 PM
- Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/12/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:12:15 PM
- Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024 • GlobeNewswire Inc. • 08/06/2024 08:36:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/24/2024 08:16:09 PM
- Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke • GlobeNewswire Inc. • 06/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:15:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:30:11 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/31/2024 08:23:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/31/2024 08:21:53 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/30/2024 08:15:08 PM
- Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier • GlobeNewswire Inc. • 05/29/2024 01:00:00 PM
- Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts • GlobeNewswire Inc. • 05/20/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/14/2024 08:15:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:30:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:15:00 PM
- Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024 • GlobeNewswire Inc. • 05/10/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:31:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/08/2024 08:56:46 PM
- Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering • GlobeNewswire Inc. • 05/07/2024 02:15:00 AM
- Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®) • GlobeNewswire Inc. • 05/06/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM